PharmaCyte Biotech Raises $7 Million in Capital Financing

PharmaCyte Biotech has raised $7 million in a capital raise led by existing investors. The financing involves the sale of 7,000 shares of Series C convertible preferred stock, convertible into 7,000,000 common stock shares, and warrants to purchase up to 7,000,000 common stock shares. The deal is expected to close on August 19, 2025. The financing strengthens PharmaCyte's balance sheet and positions it to pursue strategic alternatives that can maximize shareholder value.

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) has secured $7 million in a capital raise led by existing investors. The financing involves the sale of 7,000 shares of Series C convertible preferred stock, with a stated value of $1,000 per share, convertible into an aggregate of 7,000,000 shares of common stock. Additionally, unregistered common stock purchase warrants to purchase up to an aggregate of 7,000,000 shares of common stock are included in the private placement. The deal is expected to close on August 19, 2025, subject to customary closing conditions.

The financing, priced at a premium to the company's current market price, reflects strong confidence in PharmaCyte's future and will significantly strengthen its balance sheet. This capital infusion will enable the company to enhance shareholder value and pursue strategic alternatives that can maximize long-term returns for its stockholders.

The shares of preferred stock have a conversion price of $1.00 per share of common stock and accrue a 7.0% quarterly dividend payable in cash. The warrants have an exercise price of $1.00 per common share, are exercisable immediately, and are exercisable for a term of five years from the date of issuance. The securities in the private placement were offered and sold in transactions exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act, and in reliance on similar exemptions under applicable state laws.

PharmaCyte has agreed to file a registration statement with the SEC registering the resale of the shares of common stock issuable upon conversion of the preferred stock and exercise of the warrants issued in connection with the private placement. This press release is not an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

References:
[1] https://www.stocktitan.net/news/PMCB/pharma-cyte-biotech-inc-announces-7-million-capital-raise-led-by-0lbgsrp1kgd9.html
[2] https://www.businesswire.com/news/home/20250818528622/en/PharmaCyte-Biotech-Inc.-Announces-%247-Million-Capital-Raise-Led-by-Existing-Investors